Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 3c

Aurinia Reports First Quarter Financial Results and Operational Highlights

May 10, 2018 4:02 PM EDT

AURORA Phase III Trial in lupus nephritis remains on track

Trials in FSGS and Dry Eye expected to begin in June 2018

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (Aurinia or the Company) has released its financial results for the first quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.

Our first quarter has been characterized by diligently executing our clinical programs. We remain on track to complete recruitment for our Phase III trial in lupus... More